Abstract
BackgroundTargeted therapies and immunotherapies are first-line treatments for patients with advanced melanoma. Serine–threonine protein kinase B-RAF (BRAF) and mitogen-activated protein kinase (MEK) inhibition leads to a 70% response rate in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have